Tag Archives: R&D
By Reid Paul | Published: February 10, 2012
By Julian Upton | Published: February 2, 2012
UK Waits for AZ Job Cut Breakdown As this blog was posted, AstraZeneca was still keeping the world in suspense as to a further breakdown of its announced 7,300 job cuts. The company’s UK staff assembled for a meeting at 10 am, but as of lunchtime there was still no confirmation of the actual numbers , [...]
By William Looney | Published: January 11, 2012
Estimates of what it takes to deliver a compound to market are more than an academic exercise — such data has an increasingly important on-the-ground impact on industry revenues, because if you cannot justify your costs how do you expect to prevail on price?
By Jennifer Ringler | Published: December 5, 2011
The hard (declining) numbers of approved NMEs in the past 10 to 15 years tell a powerful story. But is it the whole story?
By William Looney | Published: October 19, 2011
High in-house failure rates are slowing progress on pricing affordability, says GSK CEO Andrew Witty. If there is one message that big pharma has applied consistently over the years, it is that drug development is very expensive. Big bucks and long-term investment in the institutional know-how and capacity built exclusively through private enterprise are what count [...]